Drug profile · INN
atomoxetine hydrochloride
ATOMOXETINE HYDROCHLORIDE
atomoxetine hydrochloride (ATOMOXETINE HYDROCHLORIDE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — atomoxetine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 6
- Data quality
- 0.89
Quick answer
atomoxetine hydrochloride (ATOMOXETINE HYDROCHLORIDE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Norepinephrine transporter inhibitor
Primary target: Sodium-dependent noradrenaline transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is atomoxetine hydrochloride?
atomoxetine hydrochloride (ATOMOXETINE HYDROCHLORIDE) is a norepinephrine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for atomoxetine hydrochloride?
ATOMOXETINE HYDROCHLORIDE is a marketed brand name for atomoxetine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atomoxetine hydrochloride?
atomoxetine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.